Related and Nonrelated Parties [Axis] Nonrelated Party [Member] Affiliated Entity [Member] Related Party [Member] Short-Term Debt, Type [Axis] Convertible Notes Payable [Member] Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Subscription Receivable [Member] Retained Earnings [Member] Treasury Stock, Common [Member] AOCI Attributable to Parent [Member] Asset Acquisition [Axis] Stella Purchase Agreement [Member] Intangible Asset, Finite-Lived, Class [Axis] Technology-Based Intangible Assets [Member] Trade Names [Member] Intellectual Property [Member] Customer Relationships [Member] C L I A License [Member] Debt Instrument [Axis] Note [Member] Convertible Notes Payable January Labrys Note [Member] Investment Type [Axis] January Labrys S P A [Member] March Labrys Note [Member] March Labrys S P A [Member] Convertible Note [Member] First Twenty Twenty Six Future Receipts Financing Agreement [Member] Loans Payable Second Twenty Twenty Six Future Receipts Financing Agreement [Member] Non-Convertible Promissory Notes [Member] CEO Loan [Member] Class of Warrant or Right [Axis] CEO Warrants [Member] 2024 Term Note [Member] Unaffiliated Investor Loan [Member] Unaffiliated Investor Warrants [Member] First August 2025 Note [Member] Loans Payable [Member] Convertible Debt [Member] Second August 2025 Note [Member] Third August 2025 Notes [Member] Third August 2025 Note [Member] November 2025 Note [Member] First December 2025 Note [Member] Second December 2025 Note [Member] August 2025 Future Receipts Financing Agreements [Member] Libertas Financing Agreement [Member] August Warrants [Member] September 2025 Future Receipts Financing Agreements [Member] July 2025 Notes [Member] July Warrants [Member] Unusual or Infrequent Item, or Both [Axis] ERC Claim and Risk Participation Agreement [Member] Counterparty Name [Axis] 1861 Acquisition LLC [Member] ERC Claim [Member] Twenty Twenty Four Collateralized Loan Agreement [Member] Twenty Twenty Five Collateralized Loan Agreement [Member] WestPark Capital, Inc [Member] Sale of Stock [Axis] At the Market Offering [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Stock Purchase Agreement [Member] Plan Name [Axis] 2025 Directors Plan [Member] Amended 2022 Directors Plan [Member] 2022 Directors Plan [Member] 2025 Plan [Member] 2022 Plan [Member] Warrant [Member] Linebacker License Agreements [Member] Award Type [Axis] New Drug Application [Member] BE Smart License Agreements [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Business Combination [Axis] CPM [Member] Geographic Distribution [Axis] Old Bridge, New Jersey [Member] New York Second Floor Lease [Member] New York First Floor Lease [Member] Segments [Axis] Diagnostic Services Segment [Member] Consumer Products Segment [Member] Unallocated Corporate [Member] Antidilutive Securities [Axis] Common Stock Purchase Warrants [Member] Share-Based Payment Arrangement, Option [Member] Convertible Debt Securities [Member] Title and Position [Axis] Chief Operating Officer [Member] Related Party Transaction [Axis] Consulting Services [Member] Former Chief Operating Officer [Member] Chief Executive Officer [Member] Disposal Group Classification [Axis] Discontinued Operations, Held-for-Sale or Disposed of by Sale [Member] Unique Name [Axis] PMI Note [Member] Capital Leases [Member] Current and Accrued Payables [Member] Existing Loan From Affiliates [Member] Accrued Interest [Member] Investment, Name [Axis] PDX [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Measurement Frequency [Axis] Fair Value, Recurring [Member] Liability Class [Axis] Derivative [Member] July 2025 Notes [Member] August Future Financing Agreement [Member] Measurement Input Type [Axis] Measurement Input, Exercise Price [Member] Measurement Input, Expected Term [Member] Measurement Input, Price Volatility [Member] Measurement Input, Risk Free Interest Rate [Member] Measurement Input, Expected Dividend Rate [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Entity Listing, Par Value Per Share Defined Benefit Plan [Table] Defined Benefit Plan Disclosure [Line Items] ASSETS Current assets Cash and cash equivalents Accounts receivable, net Inventory, net Prepaid expenses and other current assets Total current assets Property, plant and equipment, net Investment in unconsolidated affiliates Prepaid expenses, net of current portion Intangible assets, net Goodwill Other assets TOTAL ASSETS LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities Accounts payable Accrued advertising and other allowances Finance lease liabilities Short-term loan payable, net of discount Short-term convertible notes payable, net of discount of $511 and $157, respectively Derivative liability Deferred revenue Income tax payable Other current liabilities Total current liabilities Non-current liabilities: Due to sellers (see Note 3) Deferred revenue, net of current portion Finance lease liabilities, net of current portion Total non-current liabilities Total liabilities COMMITMENTS AND CONTINGENCIES Stockholders’ equity (deficit) Preferred stock authorized 1,000,000, $0.0005 par value, no shares issued and outstanding Common stock authorized 1,000,000,000, $0.0005 par value, 14,016,024 and 8,966,406 shares outstanding, respectively Additional paid-in capital Accumulated deficit Treasury stock, at cost, 869,208 and 869,208 shares, respectively Accumulated other comprehensive loss Total stockholders’ equity (deficit) TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFECIT) Discount, current Preferred stock shares authorized Preferred stock par value Preferred stock shares issued Preferred stock shares outstanding Common stock shares authorized Common stock par value Common stock shares outstanding Treasury Stock, Common, Shares Treasury stock, common shares, collateral Common stock shares issued not disclosed Income Statement [Abstract] Revenues, net Cost of revenues Gross profit Operating expenses: General and administration Research and development Total operating expenses Loss from operations Other income (expenses) Loss from investment in unconsolidated affiliates Change in fair value of derivative liability Interest expense Debt extinguishment loss Loss on issuance of debt Income from disposal of fixed assets Other expense Loss from operations before income taxes Income tax expense Loss from continuing operations after income taxes Discontinued operations: Loss from discontinued operations, net of tax Gain from disposal of discontinued operations Income from discontinued operations Net (loss) income Net earnings (loss) per share: Weighted average common shares outstanding: Basic Diluted Loss from continuing operations, basic Loss from continuing operations, diluted Income from discontinued operations, basic Income from discontinued operations, diluted Net loss (earnings) per share, basic Net loss (earnings) per share, diluted Statement [Table] Statement [Line Items] Balance Balance, shares Issuance of common stock for cash, net of offering cost of $75 Issuance of common shares and treasury shares for cash, net of offering cost of $75, shares Issuance of common stock as commitment fee for future financing Issuance of common stock as commitment fee for future financing, shares Issuance of common shares and warrants in conjunction with debt issuance Issuance of common shares and warrants in conjunction with debt issuance, shares Issuance of common stock to convert outstanding debt Issuance of common stock to convert outstanding debt, shares Stock-based compensation Net income (loss) Unrealized gain on marketable debt securities Balance Balance, shares Statement of Stockholders' Equity [Abstract] Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Prepaid expense Statement of Cash Flows [Abstract] Cash flows from operating activities Net loss from continuing operations Less: income (loss) from discontinued operations, net of tax Adjustments to reconcile net loss to net cash (used in) provided by operating activities: Depreciation and amortization Amortization of debt discount Amortization on operating lease right-of-use assets Loss from investment in unconsolidated affiliates Loss on issuance of debt Loss (gain) from disposal of fixed assets Stock-based compensation expense Change in fair value of derivative liability Debt extinguishment loss Changes in operating assets and liabilities: Accounts receivable Inventory Prepaid expenses and other current assets Accounts payable and accrued expenses Accrued diagnostic services Deferred revenue Lease liabilities Income tax payable Other liabilities Net cash used in operating activities - continuing operations Net cash provided by operating activities - discontinued operations Net cash used in operating activities Cash flows from investing activities Proceeds from sale of fixed assets Capital expenditures Net cash provided by investing activities - continuing operations Net cash provided by investing activities - discontinued operations Net cash provided by investing activities Cash flows from financing activities Proceeds from issuance of common shares, net Proceeds from issuance of note payable, net Proceeds from issuance of convertible notes payable Repayment of note payable Net cash provided by financing activities - continuing operations Net cash used in financing activities - discontinued operations Net cash provided by financing activities Decrease in cash and cash equivalents Cash and cash equivalents at the beginning of the period Cash and cash equivalents at the end of the period Supplemental disclosures: Cash paid for income taxes Interest payments Supplemental disclosure of non-cash investing and financing activities: Issuance of common stock as commitment fee for future financing Issuance of common stock to convert outstanding debt Pay vs Performance Disclosure [Table] Executive Category [Axis] Individual [Axis] Adjustment to Compensation [Axis] Measure [Axis] Pay vs Performance Disclosure, Table Company Selected Measure Name Named Executive Officers, Footnote Peer Group Issuers, Footnote Changed Peer Group, Footnote PEO Total Compensation Amount PEO Actually Paid Compensation Amount Adjustment To PEO Compensation, Footnote Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Compensation Actually Paid Amount Adjustment to Non-PEO NEO Compensation Footnote Equity Valuation Assumption Difference, Footnote Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Company Selected Measure Total Shareholder Return Vs Peer Group Compensation Actually Paid vs. Other Measure Tabular List, Table Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Net Income (Loss) Company Selected Measure Amount Other Performance Measure, Amount Adjustment to Compensation, Amount PEO Name Name Non-GAAP Measure Description Additional 402(v) Disclosure Pension Benefits Adjustments, Footnote Equity Awards Adjustments, Footnote Erroneously Awarded Compensation Recovery [Table] Restatement Determination Date [Axis] Restatement Determination Date Aggregate Erroneous Compensation Amount Erroneous Compensation Analysis Stock Price or TSR Estimation Method Outstanding Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Not Yet Determined Name Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery, Explanation of Impracticability Name Compensation Amount Restatement does not require Recovery Awards Close in Time to MNPI Disclosures [Table] Award Timing MNPI Disclosure Award Timing Method Award Timing Predetermined Award Timing MNPI Considered Award Timing, How MNPI Considered MNPI Disclosure Timed for Compensation Value Awards Close in Time to MNPI Disclosures, Table Name Underlying Securities Exercise Price Fair Value as of Grant Date Underlying Security Market Price Change Insider Trading Arrangements [Line Items] Material Terms of Trading Arrangement Name Title Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted Adoption Date Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated Termination Date Expiration Date Arrangement Duration Aggregate Available Insider Trading Policies and Procedures [Line Items] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Not Adopted Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization and Business Accounting Policies [Abstract] Summary of Significant Accounting Policies Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract] Asset Acquisition Intangible Asset, Goodwill and Other [Abstract] Intangible Assets, Net Debt Disclosure [Abstract] Outstanding Debt Equity [Abstract] Stockholders’ Equity Income Tax Disclosure [Abstract] Income Taxes Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Leases Leases Segment Reporting [Abstract] Segment Information Earnings Per Share [Abstract] Net Earnings (Loss) Per Share Related Party Transactions [Abstract] Related Parties Discontinued Operations and Disposal Groups [Abstract] Discontinued Operations Reorganizations [Abstract] Voluntary Bankruptcy Filing and Deconsolidation Fair Value Disclosures [Abstract] Fair Value Measurements Subsequent Events [Abstract] Subsequent Events Basis of Presentation Use of Estimates Deconsolidation of Subsidiary Discontinued Operations Reclassifications Fair Value of Financial Instruments Goodwill Revenue Recognition and Accounts Receivable Income Taxes Recently Adopted Accounting Standards Recently Issued Accounting Standards, Not Yet Adopted Schedule of Intangible Assets Schedule Estimated Future Amortization Expense of Acquired Intangible Assets Schedule of Stock Options Activity Schedule of Warrant Activity Schedule of Quantitative Information about Operating and Finance Leases Schedule of Maturities of Finance Leases Schedule of Segment Information Schedule of Reconciliation of the Weighted Average Number of Common Shares Outstanding used in Calculating Basic and Diluted Net Loss Per Share Schedule of Anti-dilutive Securities Excluded from the Income Per Share Computation Schedule of Fair Value of the Company’s Financial Liabilities That are Measured at Fair Value On a Recurring Basis Schedule of Changes in Fair Value Schedule of Fair Value Measurement Inputs and Valuation Techniques Number of lab entities Number of licensed compounds Number of licensed compounds Asset Acquisition [Table] Asset Acquisition [Line Items] Cash paid Secured note amount Liability payoff amount Promissory note payoff amount Stock issued during period Common stock, par value Shares issued Consideration transferred Asset acquisition, contingent consideration, liability Finite-lived intangible asset, useful life Royalty percent Transaction costs Purchase price Intangible Asset, Finite-Lived [Table] Intangible Asset, Finite-Lived [Line Items] Total intangible assets, gross Estimated Useful Life (in years) Less: accumulated amortization Total intangible assets, net Remaining periods in 2026 Year ended December 31, 2027 Year ended December 31, 2028 Year ended December 31, 2029 Year ended December 31, 2030 Thereafter Amortization expense Short-Term Debt [Table] Short-Term Debt [Line Items] Interest rate Aggregate principal amount Debt instrument, convertible, threshold trading days Debt instrument, convertible, threshold trading days Proceeds from short-term debt Debt issuance costs Periodic payment Number of periodic payments Stock Issued During Period, Shares, New Issues Debt instrument, convertible, beneficial ownership limitation, percentage Debt instrument, convertible, period from issuance date Embedded derivative, fair value of embedded derivative liability Proceeds from issuance of note payable Origination fee Brokerage fee Outstanding balance Original issuance discount Debt instrument number of non convertible promissory notes issued Term note period Unvested warrants (in shares) Exercise price per share Warrants outstanding, term Warrant, fair value Expected dividend yield (per share) Expected stock price volatility (as a percent) Risk-free rate of interest (as a percent) Expected term (in years) Extinguishment of debt, amount Debt instrument, fair value disclosure Amortization of debt discount Conversion price Debt extinguishment gain Convertible note Shares of common stock Fair value of convertible note Periodic payment interest Debt instrument, periodic payment terms, balloon payment to be paid Debt instrument, number of agreements entered into agreement Debt instrument, unamortized discount (premium) and debt issuance costs, net Debt instrument, periodic payment delay from issuance date, period Net proceeds from short-term debt Repayments of short-term debt Short-term loan payable Debt instrument, original issue discount, percent Debt instrument, convertible, note conversion waiting period Warrants (in shares) Debt Conversion, Converted Instrument, Amount Debt Conversion, Converted Instrument, Accrued Interest, Amount Debt conversion, common stock Issuance of common stock to convert outstanding convertible notes and interest Employee retention credit receivable Proceeds from sale of company rights, title and interest to employee retention credit Payments of issuance costs for sale of company rights, title and interest to employee retention credit Employee retention credit receivable, amount transferred ERC claim approve or deny period (in months) Repurchase percentage Interest rate percentage on impaired amount allowed to be put back to the company Proceeds from income tax refunds Proceeds from income tax refunds portion passed through to buyer Outstanding tax liability Outstanding balance Number of common shares secured for loan Arranger fee Number of shares, outstanding, beginning Weighted average exercise price, outstanding, beginning Weighted average remaining contractual life, outstanding shares (in years) Total intrinsic value, outstanding, beginning Number of shares options granted Weighted average exercise price, granted Number of shares options forfeited Weighted average exercise price, forfeited Number of shares, outstanding, ending Weighted average exercise price, outstanding, ending Total intrinsic value, outstanding, ending Number of shares, options vested and exercisable Weighted average exercise price, options vested and exercisable Weighted average remaining contractual life, options vested and exercisable (in years) Total intrinsic value, options vested and exercisable Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Number of shares, warrants outstanding, beginning Weighted average exercise price, warrants outstanding, beginning Weighted average remaining contractual life, outstanding shares Number of shares, warrants granted Weighted average exercise price, warrants granted Number of shares, warrants outstanding, ending Weighted average exercise price, warrants outstanding, ending Number of shares, warrants vested and exercisable Weighted average exercise price, warrants vested and exercisable Weighted average remaining contractual life, warrants vested and exercisable Subsidiary or Equity Method Investee, Sale of Stock, Type [Table] Subsidiary, Sale of Stock [Line Items] ThinkEquity LLC [Member] Preferred stock, issued Dividends declared Aggregate offering price Sale of stock, commission percentage Increase in the number of shares reserved for issuance Sale of stock, consideration received on transaction Net issuance cost Equity Caoital Stock issued during the period, shares Warrants rights to acquire Warrants Exercise price Aggregate offering price Shares issued Shares authorized Increase in shares for issuance Common Stock, Capital Shares Reserved for Future Issuance Sale of Stock, Price Per Share Warrant share price Share-based compensation expense Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Loss Contingencies [Table] Loss Contingencies [Line Items] Upfront license fee License agreement term Additional payment of fee License or royalty net revenue percentage Minimum royalty Collaborative arrangement, estimated annual procedures Collaborative arrangement, estimated market opportunity value Schedule Of Quantitative Information About Operating And Finance Leases Operating lease expense Total operating lease expense Interest lease cost Depreciation expense Total finance lease expense Operating cash flows used in operating leases Weighted-average remaining lease term - finance leases (in years) Weighted-average discount rate – finance leases Finance lease asset Schedule Of Quantitative Information About Operating And Finance Leases Details Accumulated depreciation on finance lease asset Remaining periods in 2026 Year Ended December 31, 2027 Total lease payments Less present value discount Total Restructuring Cost [Table] Restructuring Cost and Reserve [Line Items] Area of real estate property Operating lease, renewal term Operating lease, monthly base rent Operating lease, liability Operating lease, settlement amount Operating lease, settlement installments Finance lease, term of contract Minimum future obligations Interest rate Finance lease liabilities Finance lease assets Segment Reporting [Table] Segment Reporting [Line Items] Consolidated net revenue Consolidated cost of revenue Total Depreciation and amortization expense Total  operating and other expenses Total loss from operations, before income taxes Total loss from operations, after income taxes Net loss from continuing operations Unallocated corporate Total assets Number of operating segments Loss from continuing operations after income taxes Income from discontinued operations, net of tax Income (loss) from discontinued operations, basic Income (loss) from discontinued operations, diluted Net loss per share, basic Net loss per share, diluted Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Anti-dilutive securities Related Party Transaction [Table] Related Party Transaction [Line Items] Related party transaction amounts Accounts payable, current Debt, face amount Number of warrants or rights outstanding Disposal Groups, Including Discontinued Operations [Table] Disposal Group, Including Discontinued Operations [Line Items] Proceeds from Divestiture of Interest in Consolidated Subsidiaries Noncash or Part Noncash Divestiture, Amount of Consideration Received Non cash or part non cash divestiture capital expenditures avoided Employee annual overhead Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax ReorganizationsTable [Table] Equity method investments Loss from investments Fair Value, off-Balance-Sheet Risk [Table] Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items] Derivative liability Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Balance at January 1, 2026 Issuance of convertible debt Debt amendment Redemptions Change in fair value Balance at March 31, 2026 Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Warrants outstanding measurement input Expected term (years) Subsequent Event [Table] Subsequent Event [Line Items] Payments acquire business gross Origination fee Business combination transferred Finite lived intangible assets amortization expense after year three Former Chief Operating Officer [Member] Inducement Option Award [Member] Share-based compensation arrangement by share-based payment award, options, granted, weighted average remaining contractual term. Share-based compensation arrangement by share-based payment award, options, grants in period, grant date fair value. Treasury stock, common shares, collateral. Debt instrument, collateral amount, shares. 2024 Collateralized Loan Agreement [Member] Debt instrument, arranger fee, percentage. 2025 Collateralized Loan Agreement [Member] Debt instrument, number of non-convertible promissory notes issued. Non-Convertible Promissory Notes [Member] CEO Loan [Member] Schedule of Warrant Activity [Table Text Block] CEO Warrants [Member] Share based compensation arrangement by share based payment award non options vested and expected to vest exercisable number. Share based compensation arrangement by share based payment award non options outstanding weighted average exercise price 1. Share based compensation arrangement by share based payment award non options outstanding granted weighted average exercise price 1. Share based compensation arrangement by share based payment award non options outstanding granted weighted average exercise price 1. Gain (loss) on issuance of debt. Share based compensation arrangement by share based payment award non options vested and exercisable weighted average remaining contractual term 2. 2024 Term Note [Member] Employee retention tax credit income. Unaffiliated Investor Loan [Member] Schedule of Share Based Payment Award Fair Value of Warrants Valuation Assumptions [Table Text Block] Unaffiliated Investor Warrants [Member] First August 2025 Note [Member] Number of periodic payments. Second August 2025 Note [Member] Upfront license fee. Linebacker License Agreements [Member] Additional payment of fee. License agreement term (in days). New Drug Application [Member] License Or royalty net revenue percentage. Equivir Licenser Agreements [Member] Collaborative arrangement, estimated market opportunity value. BE Smart License Agreements [Member] Collaborative arrangement, estimated annual procedures. Debt instrument, number of agreements entered into. Third August 2025 Notes [Member] Debt instrument, periodic payment delay from issuance date, period (in months). November 2025 Note [Member] First December 2025 Note [Member] Employee retention tax credit income. Inventory valuation reserve. Second December 2025 Note [Member] Increase decrease in accrued diagnostic services. Prepaid expense. August 2025 Future Receipts Financing Agreements [Member] Issuance of common stock as commitment fee for future financing. Libertas Financing Agreement [Member] August Warrants [Member] September 2025 Future Receipts Financing Agreements [Member] Brokerage fee. July 2025 Notes [Member] Debt instrument, original issue discount, percent. Debt instrument, convertible, note conversion waiting period. July Warrants [Member] Subscription Receivable [Member] Employee retention credit receivable. ERC Claim and Risk Participation Agreement [Member] Proceeds from sale of company rights, title and interest to employee retention credit. 1861 Acquisition LLC [Member] Payments of issuance costs for sale of company rights, title and interest to employee retention credit. Employee retention credit receivable, amount transferred. ERC claim approve or deny period (in months). Percentage of impaired amount allowed to be put back to the company. Interest rate percentage on impaired amount allowed to be put back to the company. Proceeds from income tax refunds, portion passed through to buyer. Deferred tax liabilities, amount offset from income tax refunds. Deconsolidation, Policy [Policy Text Block] Recently Issued Accounting Standards Not Yet Adopted [Policy Text Block] Sale of stock, aggregate initial offering price, maximum. WestPark Capital, Inc [Member] At the Market Offering [Member] Sale of stock, commission percentage. ThinkEquity LLC [Member] CPM [Member] Old Bridge, New Jersey [Member] Lessee, operating lease, monthly Base rent. Operating lease, surrender settlement amount, monthly. Operating lease, number of surrender settlement installments. Operating lease, liability, decrease from lease termination. Operating lease, right-of-use asset, decrease from lease termination. Lessee, finance lease, interest rate. Finance lease cost Disposal group, including discontinued operation, finance lease, right-of-use asset, after accumulated amortization. Disposal group, including discontinued operation, Finance lease, right-of-use asset, accumulated amortization. Corporate Stock [Member] Payments for asset acquisition. Stella Purchase Agreement [Member] Asset acquisition, consideration transferred, liability payoff. Asset acquisition, consideration transferred, promissory note payoff. Asset acquisition, shares issued and issuable, value per share. Common stock, increase (decrease) in capital shares reserved for future issuance. Purchase agreement, royalty percent. Asset acquisition, transaction costs. 2025 Directors Plan [Member] Amended 2022 Directors Plan [Member] 2022 Directors Plan [Member] Amended 2010 Directors Plan [Member] 2025 Plan [Member] ERC Claim [Member] 2022 Plan [Member] 2010 Plan [Member] 2018 Stock Incentive Plan [Member] Operating lease, non-refundable security deposit, writeoff. Unsecured promissory notes non-current. Unsecured Promissory Notes [Member] Unsecured Long Term Debt [Member] CEO Options [Member] New York Second Floor Lease [Member] New York First Floor Lease [Member] Number of lab entities filed for chapter 11 reorganization. Number of licensed compounds. Number of inhibitors. BE Smart License Agreement [Member] Number of ancestry single nucleotide polymorphisms based tests equivalent description. Number of food drug and mass retail stores distribution. Diagnostic Services Segment [Member] Consumer Products Segment [Member] Unallocated Corporate [Member] Common Stock Purchase Warrants [Member] Consulting Services [Member] PMI Note [Member] Capital Leases [Member] Current and Accrued Payables [Member] Existing Loan From Affiliates [Member] Accrued Interest [Member] Non cash or part non cash divestiture capital expenditures avoided. Non cash or part non cash divestiture employee annual overhead transferred. Pharmaloz Manufacturing Inc and Pharmaloz Real Estate Holdings Inc [Member] Disposal group including discontinued operation research and development expense. Disposal group including discontinued operation restricted cash. Disposal group including discontinued operation notes payable current. Disposal group including discontinued operation finance lease liability current. Disposal group including discontinued operation long term debt noncurrent. Disposal group including discontinued operation long term debt noncurrent. PDX [Member] Warrant liability fair value disclosure. Loan Agreements [Member] July 2025 Notes [Member] August Future Financing Agreement [Member] Common stock shares issued not disclosed. July 2025 Notes [Member] [Default Label] Assets, Current Liabilities, Current Liabilities, Noncurrent Liabilities Treasury Stock, Common, Value Liabilities and Equity Gross Profit Operating Expenses Operating Income (Loss) Interest Expense, Nonoperating Income Tax Expense (Benefit) Equity, Including Portion Attributable to Noncontrolling Interest Shares, Outstanding Gain (Loss) on Disposition of Property Plant Equipment Increase (Decrease) in Accounts Receivable Increase (Decrease) in Inventories Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Deferred Revenue Increase (Decrease) in Income Taxes Payable Cash Provided by (Used in) Operating Activity, Continuing Operation Cash Provided by (Used in) Operating Activity, Discontinued Operation Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Payments to Acquire Productive Assets Cash Provided by (Used in) Investing Activity, Continuing Operation Cash Provided by (Used in) Investing Activity, Discontinued Operation Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Repayments of Notes Payable Cash Provided by (Used in) Financing Activity, Continuing Operation Cash Provided by (Used in) Financing Activity, Discontinued Operation Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation StockIssuedAsCommitmentFeeForFutureFinancing IssuanceOfCommonStockToConvertOutstandingDebt Forgone Recovery, Individual Name Outstanding Recovery, Individual Name Awards Close in Time to MNPI Disclosures, Individual Name Trading Arrangement, Individual Name Lessee, Finance Leases [Text Block] Discontinued Operations, Policy [Policy Text Block] Goodwill and Intangible Assets, Policy [Policy Text Block] Income Tax, Policy [Policy Text Block] NumberOfInhibitors Intangible Asset, Finite-Lived, Accumulated Amortization Intangible Asset, Finite-Lived, after Accumulated Amortization Debt Instrument, Convertible, Threshold Trading Days Amortization of Debt Discount (Premium) Long-Term Debt Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice1 ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsVestedAndExpectedToVestExercisableNumber ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsVestedAndExercisableWeightedAverageExercisePrice1 Sale of Stock, Number of Shares Issued in Transaction Operating Lease, Expense FinanceLeaseCost Operating Lease, Payments Finance Lease, Liability, to be Paid, Remainder of Fiscal Year Finance Lease, Liability, Undiscounted Excess Amount LesseeFinanceLeaseInterestRate WarrantLiabilityFairValueDisclosure Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value OriginationFee